Merus reports Q2 EPS (81c), consensus (76c)

Reports Q2 revenue $7.33M, consensus $8.49M. The company said, “Petosemtamab has already demonstrated potential for best in class efficacy with a favorable safety profile in both 1L and 2L+ HNSCC, major areas of unmet medical need. I’m also looking forward to evaluating petosemtamab in mCRC, another potential important opportunity. With the addition of Dr. Fabian Zohren as CMO and the recent successful equity financing raising $460M gross proceeds, we are well positioned for our ambitious phase 3 trial plans for petosemtamab in HNSCC and beyond.”